Ceritinib is an aminopyrimidine with the structure of 2,6-diamino-5-chloropyrimidine, where the amino groups at positions 2 and 6 are substituted with 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl, respectively. It is used in the treatment of ALK-positive metastatic non-small cell lung cancer. Ceritinib functions as an antineoplastic agent and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It is also classified as an aromatic ether, organochlorine compound, secondary amino compound, piperidine, and sulfone.
